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Abstract
BACKGROUND
Acute recurrent pancreatitis (ARP) is characterized by episodes of acute
pancreatitis in an otherwise normal gland. When no cause of ARP is identifiable,
the diagnosis of "idiopathic" ARP is given. Mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene increase the risk of ARP by 3-
to 4-times compared to the general population, while cystic fibrosis (CF) patients
present with a 40- to 80-times higher risk of developing pancreatitis.
CASE SUMMARY
In non-classical CF or CFTR-related disorders, CFTR functional tests can help to
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ensure a proper diagnosis. We applied an individualized combination of
standardized and new CFTR functional bioassays for a patient referred to the
Verona CF Center for evaluation after several episodes of acute pancreatitis. The
CFTR genotype was G542X+/- with IVS8Tn:T7/9 polymorphism. The sweat (Cl-)
values were borderline. Intestinal current measurements were performed
according to the European Cystic Fibrosis Society Standardized Operating
Procedure. Recent nasal surgery for deviated septum did not allow for nasal
potential difference measurements. Lung function and sputum cultures were
normal; azoospermia was excluded. Pancreas divisum was excluded by imaging
but hypoplasia of the left hepatic lobe was detected. Innovative tests applied in
this case include sweat rate measurement by image analysis, CFTR function in
monocytes evaluated using a membrane potential-sensitive fluorescent probe,
and the intestinal organoids forskolin-induced swelling assay.
CONCLUSION
Combination of innovative CFTR functional assays might support a controversial
diagnosis when CFTR-related disorders and/or non-classical CF are suspected.
Key words: Recurrent acute pancreatitis; Cystic fibrosis; Cystic fibrosis transmembrane
conductance regulator function; Intestinal current; Organoids; Sweat test; Controversial
diagnosis; Case report
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: When the diagnosis of "idiopathic" recurrent acute pancreatitis is given, non-
classical cystic fibrosis or disorders related to mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene are sometimes suspected when the
phenotype is consistent with cystic fibrosis. Combination of innovative CFTR functional
assays might support a controversial diagnosis, contributing to better definitions of these
clinical entities.
Citation: Caldrer S, Bergamini G, Sandri A, Vercellone S, Rodella L, Cerofolini A, Tomba F,
Catalano F, Frulloni L, Buffelli M, Tridello G, de Jonge H, Assael BM, Sorio C, Melotti P.
Cystic fibrosis transmembrane conductance regulator functional evaluations in a G542X+/-
IVS8Tn:T7/9 patient with acute recurrent pancreatitis. World J Clin Cases 2019; 7(22): 3757-
3764
URL: https://www.wjgnet.com/2307-8960/full/v7/i22/3757.htm
DOI: https://dx.doi.org/10.12998/wjcc.v7.i22.3757
INTRODUCTION
Cystic fibrosis (CF) is the most common lethal genetic disease in Caucasians, affecting
around  1  in  3000  live  births.  Its  underlying  etiology  is  disease-causing  genetic
mutations occurring on both alleles of the cystic fibrosis transmembrane conductance
regulator (CFTR)  gene[1].  Within the spectrum of disorders associated with CFTR
dysfunction is recurrent-acute (APR) and chronic pancreatitis that can harbor CFTR
mutations within classic CF or CFTR-related pancreatitis[2].
ARP and chronic pancreatitis due to CFTR dysfunction can be indistinguishable
from idiopathic (I) ARP in its initial clinical presentation[3].
The  most  recent  consensus  statement  from  the  United  States  Cystic  Fibrosis
Foundation[4] provides for a diagnosis of CF to be made in individuals who present
with a characteristic clinical phenotype or a history of CF in a sibling, in the presence
of an abnormal sweat chloride value ≥ 60 mmol/L and/or two CF-causing mutations.
Identification of CFTR  mutations on both alleles is  not sufficient to establish the
diagnosis  of  CF especially when one or  both are not  designated disease-causing
mutations[5].  While  the  management  of  pancreatitis  associated with  CF or  CFTR
mutations per se is currently not different from that of other forms of pancreatitis, the
main concerns in these patients  are a  progression from pancreatic  sufficiency to
pancreatic insufficiency and increased risk of developing CF disease and/or disease
in other CF-affected organs (e.g., bronchiectasis)[2,6], as such these patients should be
referred to specialized gastroenterologists or centers with expertise in CF for proper
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management.
A  careful  evaluation  of  CFTR  function  is  therefore  important  for  proper
management of these patients. Herein, we describe a patient who was evaluated by
different assays targeting different tissues/cell types known to express CFTR, some of
which  are  standardized  for  clinical  application,  such  as  the  intestinal  current
measurement (ICM)[7] and nasal potential difference (NPD) measurement[8], or are
considered as emerging approaches. The latter include the primary forskolin-induced
swelling  (FIS)  assay  on  intestinal  organoids[9],  assessment  of  CFTR  function  in
leukocytes[10], as well as the beta-adrenergic/cholinergic imaged sweat test[11].
CFTR functional assays
Intestinal current measurement:  For the case described herein, ion transport was
studied by ICM in rectal biopsies according to the ICM European CF Society Standard
Operating Procedure. The transepithelial short-circuit current (Isc) across the tissue
was registered in recirculating Ussing chambers, as described previously[7]. Briefly,
superficial rectal biopsies were taken by forceps, mounted in Ussing chambers, and
incubated  with  buffer  solution  at  37  °C.  Basal  potential  difference,  Isc,  and
transepithelial resistance were determined. The Isc, as a direct measure for the net
movement of ions across the epithelium, was recorded for 60-75 min after adding
amiloride,  indomethacin,  carbachol,  3-isobutyl-1-methylxanthine  (IBMX),  and
forskolin, 4,4-diisothiocyanostilbene-2,2-disulfonic acid, and histamine to the mucosal
and/or serosal side (referred to here as M and S, respectively). Responses to these
compounds were detected and analyzed using PowerLab software version 7, and the
outcome  was  calculated  using  the  cumulative  Isc  response  to  carbachol,
forskolin/IBMX and histamine[7].
Crypt isolation and organoids culture from human biopsies:  Human intestinal
biopsies were washed with cold complete chelation solution and incubated with 10
mmol/L EDTA for 30-60 min at 4 °C. Supernatant was harvested and EDTA was
washed away. Crypts were isolated by centrifugation and embedded in Matrigel
(growth factor reduced,  phenol-free;  BD Biosciences,  Franklin Lakes,  NJ,  United
States) and seeded (50-200 crypts per 50 μL Matrigel per well) in 24-well plates. The
Matrigel was polymerized for 10 min at 37 °C and immersed in complete culture
medium  supplemented  with  1%  penicillin/streptomycin,  10  mmol/L  HEPES,
Glutamax,  N2,  B27  (all  from Invitrogen,  Carlsbad,  CA,  United States),  1  μM N-
acetylcysteine (Sigma-Aldrich, St Louis, MO, United States) and growth factors of 50
ng/mL  mEGF,  50%  Wnt3a  conditioned  medium  and  10%  Noggin  conditioned
medium,  20% Rspo1 conditioned medium,  10  μmol/L nicotinamide (Sigma),  10
nmol/L gastrin  (Sigma),  500  nmol/L  A83-01  (Tocris  Bioscience,  Bristol,  United
Kingdom) and 10 μmol/L SB202190 (Sigma). The medium was refreshed every 2–3 d
and organoids were passaged at about 1:5 ratio every 7–10 d. For the FIS assay, a
standard culture medium was used, composed of Advanced DMEM-F12 (Invitrogen),
1% GlutaMAX-1 (Invitrogen), 1% HEPES (Invitrogen), 1% penicillin/streptomycin
(Lonza, Basel, Switzerland) and 1% Primocin (Invitrogen).
Quantification of FIS: The procedure used was adapted slightly from the method
described by Dekkers et al[9]. Human organoids at the second split were seeded on a μ-
Slide 8 well chamber (80826; Ibidi, Martinsried, Germany) in 5 µL of 50% Matrigel
containing about 20 organoids in 200 µL culture medium. Two days after the seeding,
the organoids were incubated for  30  min with 100 µL standard culture  medium
containing 3 µmol/L Calcein-green (Invitrogen), and stimulated with forskolin (5 µM)
for direct analysis by confocal live cell microscopy (TCS-SP5 inverted microscope;
Leica, Wetzlar, Germany). For CFTR inhibition, organoids were pre-incubated (60
min)  with  50  µmol/L  CFTR-inh172  (Sigma).  The  organoid  volume  (xyz  plane)
increase, relative to t = 0 of forskolin treatment, was normalized to baseline (= 100%)
and  quantified  using  IMMARIS  7.2.1  software  (Bitplane,  Zurich,  Switzerland).
Occasionally, cell debris and unviable structures were manually excluded from the
imaging analysis by use of defined settings.
Cell  membrane  depolarization  assay:  The  potential-sensitive  probe  bis-(1,3-
diethylthiobarbituric  acid)  trimethine  oxonol  (DiSBAC2(3);  Life  Technologies,
Carlsbad, CA, United States) was used to monitor the CFTR-dependent membrane
potential  (Vm) changes in monocytes as previously described[10].  The ΔFt curves,
computed as the difference between mean ΔFt (stimulus) and mean ΔFt (vehicle) in
the last  5  min of  recording,  was termed “CF index” and was positive in healthy
subjects and negative in CF patients, with intermediate values in healthy carriers[10].
Bubble sweat test (BST) protocol:  For the drug delivery and imaging of M- and
CFTR-dependent secretion (C)-sweating, injection area on the subject’s right forearm
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was chosen immediately before the test. An oil reservoir was placed and fixed on the
arm, and the circular area (of the reservoir) was marked with three black dots of equal
distance along the circumference. The measurement procedure for M- and C-sweat is
described in the Supplementary Material.
In  the  measurement  of  sweat  secretion  for  both  phases,  pictures  were  taken
manually using ImageJ software. Starting from the image taken at the end of the M-
phase,  sweat  bubbles  were  numbered  progressively  according  to  the  following
criteria[11]: (1) Bubbles must have clear and round outlines; (2) Their volumes must
increase during the measurement period; and (3) The location of a C-sweat bubble
must correspond to an M-sweat bubble.
Mapped glands were then superimposed on the image obtained at the end of the C-
phase. Both images were saved as JPEG format and analyzed by ImageJ software that
allows measurement of the diameter of each bubble and automatically calculates the
volume. The average sweat rates of M- and C-sweating were finally determined by
calculating the sweat volume secreted per unit of time.
CASE PRESENTATION
Chief complaints
A 44-year old male patient heterozygous for the nonsense CFTR mutation G542X was
referred to our Center for evaluation. Denaturing Gradient Gel Electrophoresis and
Reverse  Dot  Blot  (kit  INNOLiPA  CFTR  Deletions  +6)  were  performed  without
detection of any other mutation (detection rate 98%). The status of the other family
members was referred “healthy” by the patient except her sister with CFTR genotype
G542X+/- who had recurrent bronchitis, normal sweat test and NPD, not available for
all the tests performed for his brother.
History of present illness
The patient had experienced several episodes of acute pancreatitis since the age of 26
years.
History of past illness
The patient reported having been a smoker for 20 years (15 cigarettes per day), until
2010. During the years of smoking, he had occasional bronchitis (< 1 episode per
year),  sometimes requiring oral antibiotic treatment.  He also declared occasional
alcohol  intake  on  the  weekends,  before  2000  (Table  1).  His  sister  had  recurrent
bronchitis that disappeared after stopping smoking; she was a carrier of the G542X
CFTR mutation.
Physical examination
Physical  examination  revealed  positive  Ewing’s  sign  but  other  examinations
produced negative findings, in particular for thoracic auscultation and abdominal
palpation. There was no digital clubbing. Lung function was normal.
Laboratory testing
Sweat chloride values,  obtained by the Gibson and Cooke method[12],  were 41-45
mEq/L. Sputum cultures were negative for Haemophilus parainfluenzae. Congenital
bilateral absence of the vas deferens, which is the CF phenotype associated with the
mildest  impairment  of  CFTR  function,  was  excluded  based  on  absence  of
azoospermia[5].  Recent  nasal  surgery  for  deviation  of  the  nasal  septum  and  its
complications  of  scars  in  both  nostrils  precluded  the  performance  of  NPD
measurements  or  of  nasal  brushing.  Occasionally  (from  2000  to  2014  once  or
twice/year,  first  episode in 2000),  high serum levels of  amylase and lipase were
detected.
Imaging examination
X-ray examination showed modest hypertrophy of the inferior turbinates. Thoracic
computed tomography scan showed evidence of colecystectomy and hypoplastic left
hepatic lobe.
Genetic examination
Genetic testing for mutations associated with pancreatitis in SPINK1 and PRSS1 genes
provided negative results. Sequencing of entire coding regions of both genes was
performed with diagnostic efficiency about 80%.
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Table 1  Medical history of the patient
Year Clinical condition
1999 Pancreatitis
Before 2000 Heartburn and gastric reflux; occasional alcohol intake on the weekends
1991-2010 Smoker (15 cigarettes per day)
2006 Sinusitis (1 episode)
2007-2014 Bronchitis once a year
FINAL DIAGNOSIS
CFTR-related pancreatitis.
TREATMENT
ICMs were performed on four rectal biopsies, following the European Cystic Fibrosis
Society ICM SOP (http://qa.ecfs.eu/ecfs_dnwg), and showed tracings consistent with
a non-CF pattern (Figure 1).  In this case, the cumulative Isc value of carbachol +
forskolin/IBMX + histamine, proposed by Derichs et al[7] as a diagnostic parameter,
was  87.4  µA/cm²,  with  a  cut-off  of  34  µA/cm²  between  non-CF  and  CF  with
pancreatic sufficiency (i.e., being inconsistent with the diagnosis of CF).
In order to cross-validate alternative assays using alternative primary cell samples,
we tested CFTR function in monocytes. The CFTR agonists used in testing were 500
µmol/L 8-Br-cAMP (B5386;  Sigma),  10  µmol/L forskolin  and 100 µmol/L IBMX
(I7018; Sigma), added 5 min after the start of recording. We had previously defined
the CF index (CFI) according to the outcome of this assay and showed positive values
in non-CF subjects, in contrast to negative values in CF patients[10]. In that study, CFTR
activation was found in the ARP patient, a healthy carrier, and in a non-CF donor but
not  in  the  CF patient  used as  reference.  In  cases  of  ARP,  the  positive  CFI  (+44)
indicates a response to CFTR stimulation within the positive range, as obtained in
healthy carriers and non-CF donors (Figure 2A).
We also developed intestinal organoids from the same biopsies utilized for ICM
and performed the FIS assay, as described by Dekkers et al[9] (Figure 2B). Organoids
obtained from our ARP patient carrying the G542X+/- mutation, a healthy donor, and
a CF patient (F508del+/+), were stimulated with 5 μM forskolin and analyzed by
confocal  live cell  microscopy.  The organoids’  volume (xyz plane)  was increased
relative to t = 0 of forskolin treatment and was normalized to the baseline (= 100%);
volume changes were evaluated for 90 min and quantified automatically (by the
Bitplane microscopy image analysis software). The normalized volume increase was
117.44 ± 5.7 (mean ± SE), which is consistent with a non-CF phenotype. Moreover,
before stimulation, the ARP organoids showed a spherical appearance similar to non-
CF organoids, suggesting the presence of functional CFTR.
We finally tested the patient’s CFTR function in vivo by measuring individual sweat
gland cells through computation of the ratio between CFTR-dependent (C-sweat,
evoked by a beta-adrenergic cocktail) and CFTR-independent (M-sweat, stimulated
by methacholine) sweat secretion rates from multiple individual sweat glands. We
obtained average ratios showing an approximately linear readout of CFTR function,
as previously described[11,13]. The mean ratio was 0.20 in the non-CF samples and 0.10
in the healthy carrier samples but 0.00 in the CF patient, as seen in all the CF patients
tested at our Center. These collective results obtained on the same day were consistent
with values previously obtained at our site[13]. For our G542X+/- patient with ARP,
the C/M ratio value was 0.10, overlapping our historical results of healthy carriers.
OUTCOME AND FOLLOW-UP
This patient was recommended to attend regularly the follow-up scheduled by the
gastroenterologist  and once-twice/year the Cystic  Fibrosis  Center in order to be
monitored  for  possible  new  clinical  signs,  in  particular  those  related  to  CFTR
dysfunction.
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Figure 1
Figure 1  Results of standardized cystic fibrosis transmembrane conductance regulator functional test. Intestinal current measurement tracings from the
controversial clinical case (presented herein), cystic fibrosis (CF) patients with pancreatic insufficiency-CF or pancreatic sufficiency-CF and control (non-CF donor). As
shown in the top panel, there were positive tissue responses to forsk/IBMX: Forskolin/3-isobutyl-1-methylxanthine, Carbachol and Histamine clearly visible in acute
recurrent pancreatitis and not consistent with CF diagnosis. ARP: Acute recurrent pancreatitis; CF: Cystic fibrosis; PI-CF: Pancreatic insufficiency-cystic fibrosis; PS-
CF: Pancreatic sufficiency-cystic fibrosis.
DISCUSSION
This case report describes, for the first time, the combination of standardized assays
with new, relatively simple and robust CFTR functional assays applied to several
tissue types expressing CFTR; the results suggest how the combination of innovative
techniques  may support  diagnosis  at  an  individual  level.  ICM and/or  NPD are
suggested according to the algorithm already published[5].  Therefore a diagnostic
algorithm for similar cases, in our opinion, should include ICM and (when possible)
generation  of  intestinal  organoids  in  order  to  obtain  samples  for  support-
ing/confirming diagnosis and (possibly) perform theratyping. The importance of
testing  different  tissue  types  lies  on  the  tissue  specificity  of  exon  skipping,
furthermore, by testing only airway tissue, we could miss to identify CFTR related
pancreatitis caused by CFTR mutations selectively affecting bicarbonate transport[14].
In fact NPD test is unable to detect such selective bicarbonate impairment while ICM
and  2D  organoids  are  methods  suitable  for  testing  both  anions  transport.  If
standardized CFTR function test are inconclusive or not possible, as NPD and sweat
chloride results in this patient, the other functional tests described can be proposed to
confirm/exclude CFTR related pancreatitis.  Recent data from the literature[11,13,15]
suggest  that  BST  can  be  more  sensitive  than  sweat  chloride  measurements  for
monitoring CFTR improvement during CFTR targeted therapies, making this assay
particularly suitable to this aim. Exclusion of CF and CRD is very important when
other causes of pancreatitis are suspected (i.e., drug, gallstones, or sphincter of Oddi
dysfunction), which may result in therapeutic approaches with limited/no effects (i.e.,
drug withdrawal, cholecystectomy, or endoscopic sphincterotomy respectively) in
patients with recurrent pancreatitis.
For  the  case  presented  herein,  the  results  of  a  number  of  different  tests,
standardized as well as experimental, excluded the diagnosis of CF. All the recently
developed  assays  described  in  this  study-involving  the  intestinal  organoids,
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Figure 2
Figure 2  Results of cystic fibrosis transmembrane conductance regulator functional assays. A: Membrane depolarization by single cell fluorescence analysis
performed in monocytes with (black trace) and without (white trace) stimulus added at 5 min. The cystic fibrosis (CF) index was calculated as reported[10]; B:
Normalized volume increase of individual organoids obtained during Forskolin-induced swelling assay. Organoids were obtained from the acute recurrent pancreatitis
patient carrying the mutation G542+/-, a non-CF subject with or without pre-incubation with cystic fibrosis transmembrane conductance regulator-inh72 and with
stimulation with the potentiator VX770, and a CF patient. Box and whisker plots (10th-90th percentiles) correspond to the normalized volume increase with respect to
the baseline for each subject; the midline in boxes indicates median. Symbols indicate significant differences (one way-ANOVA; aP < 0.05; bP < 0.02) identified by
Dunn’s method to compare all groups vs the non-CF control. CFTR: Cystic fibrosis transmembrane conductance regulator; CF: Cystic fibrosis; CFI: Cystic fibrosis
index; FIS: Forskolin-induced swelling.
leukocytes, and individual sweat glands-provided results consistent with those of
ICM  which,  according  to  the  currently  suggested  diagnostic  algorithm,  was
considered the only standardized CFTR functional test available for this patient[5,16].
Contraindications for NPD measurements are not rare when non-classical CF and
CRD are suspected[5,16].
In  our  opinion,  the  outcomes  of  some of  these  approaches  should  be  further
evaluated in a larger number of subjects in order to collect reference values. This
might  help  for  an  individualized  diagnostic  approach  considering  sensibility,
specificity, costs, and feasibility. When used alone or in combination, selected on the
basis of specialized centres availability and patient’s conditions, these tests might be
valuable not only for diagnostic applications but also for theratyping approaches[17,18].
ACKNOWLEGEMENTS
This case report was presented at the following conferences: 39th ECFS Conference (8-
WJCC https://www.wjgnet.com November 26, 2019 Volume 7 Issue 22
Caldrer S et al. CFTR functional assays in pancreatitis
3763
11 June 2016 in Basel, Switzerland; as “Supporting Diagnosis With a Combination of
Standardized And New CFTR Functional Tests”) and at the 13th ECFS Basic Science
Conference 2016 (30 March-02 April 2016 in Pisa, Italy; as “Combining Standardized
and New CFTR Functional Tests for Improving Diagnosis”).
REFERENCES
1 Maitra A, Kumar V, Kumar V, Abbas A, Fausto N. Diseases of infancy and childhood. Robbins and
cotran pathologic basis of disease. Kumar V, Abbas A, Fausto N. Philadelphia: Elsevier Saunders 2005;
469-508
2 Ooi CY, Dorfman R, Cipolli M, Gonska T, Castellani C, Keenan K, Freedman SD, Zielenski J,
Berthiaume Y, Corey M, Schibli S, Tullis E, Durie PR. Type of CFTR mutation determines risk of
pancreatitis in patients with cystic fibrosis. Gastroenterology 2011; 140: 153-161 [PMID: 20923678 DOI:
10.1053/j.gastro.2010.09.046]
3 Testoni PA. Acute recurrent pancreatitis: Etiopathogenesis, diagnosis and treatment. World J
Gastroenterol 2014; 20: 16891-16901 [PMID: 25493002 DOI: 10.3748/wjg.v20.i45.16891]
4 Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA,
Rock M, Rosenfeld M, Sermet-Gaudelus I, Southern KW, Marshall BC, Sosnay PR. Diagnosis of Cystic
Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr 2017; 181S: S4-S15.e1
[PMID: 28129811 DOI: 10.1016/j.jpeds.2016.09.064]
5 Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M,
Wilschanski M, Bareil C, Bilton D, Castellani C, Cuppens H, Cutting GR, Drevínek P, Farrell P, Elborn
JS, Jarvi K, Kerem B, Kerem E, Knowles M, Macek M, Munck A, Radojkovic D, Seia M, Sheppard DN,
Southern KW, Stuhrmann M, Tullis E, Zielenski J, Pignatti PF, Ferec C. Recommendations for the
classification of diseases as CFTR-related disorders. J Cyst Fibros 2011; 10 Suppl 2: S86-102 [PMID:
21658649 DOI: 10.1016/S1569-1993(11)60014-3]
6 Gilljam M, Ellis L, Corey M, Zielenski J, Durie P, Tullis DE. Clinical manifestations of cystic fibrosis
among patients with diagnosis in adulthood. Chest 2004; 126: 1215-1224 [PMID: 15486385 DOI:
10.1378/chest.126.4.1215]
7 Derichs N, Sanz J, Von Kanel T, Stolpe C, Zapf A, Tümmler B, Gallati S, Ballmann M. Intestinal current
measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and
reference data. Thorax 2010; 65: 594-599 [PMID: 20627915 DOI: 10.1136/thx.2009.125088]
8 Naehrlich L, Ballmann M, Davies J, Derichs N, Gonska T, Hjelte L, van Konigsbruggen-Rietschel S, Leal
T, Melotti P, Middleton P, Tümmler B, Vermeulen F, Wilschanski M; ECFS Diagnostic Network Working
Group. Nasal potential difference measurements in diagnosis of cystic fibrosis: an international survey. J
Cyst Fibros 2014; 13: 24-28 [PMID: 24022019 DOI: 10.1016/j.jcf.2013.08.006]
9 Dekkers JF, Wiegerinck CL, de Jonge HR, Bronsveld I, Janssens HM, de Winter-de Groot KM,
Brandsma AM, de Jong NW, Bijvelds MJ, Scholte BJ, Nieuwenhuis EE, van den Brink S, Clevers H, van
der Ent CK, Middendorp S, Beekman JM. A functional CFTR assay using primary cystic fibrosis intestinal
organoids. Nat Med 2013; 19: 939-945 [PMID: 23727931 DOI: 10.1038/nm.3201]
10 Sorio C, Buffelli M, Angiari C, Ettorre M, Johansson J, Vezzalini M, Viviani L, Ricciardi M, Verzè G,
Assael BM, Melotti P. Defective CFTR expression and function are detectable in blood monocytes:
development of a new blood test for cystic fibrosis. PLoS One 2011; 6: e22212 [PMID: 21811577 DOI:
10.1371/journal.pone.0022212]
11 Wine JJ, Char JE, Chen J, Cho HJ, Dunn C, Frisbee E, Joo NS, Milla C, Modlin SE, Park IH, Thomas
EA, Tran KV, Verma R, Wolfe MH. In vivo readout of CFTR function: ratiometric measurement of
CFTR-dependent secretion by individual, identifiable human sweat glands. PLoS One 2013; 8: e77114
[PMID: 24204751 DOI: 10.1371/journal.pone.0077114]
12 GIBSON LE, COOKE RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the
pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959; 23: 545-549 [PMID: 13633369]
13 Bergamini G, Tridello G, Calcaterra E, Ceri S, Tagliasacchi M, Bianchi F, Monti F, Masciadri A,
Laudanna E, Peserico D, Sorio E, Esposito V, Leal T, Assael BM, Sorio C, Melotti P. Ratiometric sweat
secretion optical test in cystic fibrosis, carriers and healthy subjects. J Cyst Fibros 2018; 17: 186-189
[PMID: 29292091 DOI: 10.1016/j.jcf.2017.12.003]
14 LaRusch J, Jung J, General IJ, Lewis MD, Park HW, Brand RE, Gelrud A, Anderson MA, Banks PA,
Conwell D, Lawrence C, Romagnuolo J, Baillie J, Alkaade S, Cote G, Gardner TB, Amann ST, Slivka A,
Sandhu B, Aloe A, Kienholz ML, Yadav D, Barmada MM, Bahar I, Lee MG, Whitcomb DC; North
American Pancreatitis Study Group. Mechanisms of CFTR functional variants that impair regulated
bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis. PLoS Genet 2014; 10:
e1004376 [PMID: 25033378 DOI: 10.1371/journal.pgen.1004376]
15 Salinas DB, Peng YH, Horwich B, Wee CP, Frisbee E, Maarek JM. Image-based β-adrenergic sweat rate
assay captures minimal cystic fibrosis transmembrane conductance regulator function. Pediatr Res 2019
[PMID: 31344706 DOI: 10.1038/s41390-019-0503-8]
16 De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J, Sinaasappel M; Diagnostic
Working Group. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61: 627-635
[PMID: 16384879 DOI: 10.1136/thx.2005.043539]
17 Beekman JM, Sermet-Gaudelus I, de Boeck K, Gonska T, Derichs N, Mall MA, Mehta A, Martin U,
Drumm M, Amaral MD. CFTR functional measurements in human models for diagnosis, prognosis and
personalized therapy: Report on the pre-conference meeting to the 11th ECFS Basic Science Conference,
Malta, 26-29 March 2014. J Cyst Fibros 2014; 13: 363-372 [PMID: 24882694 DOI:
10.1016/j.jcf.2014.05.007]
18 Char JE, Wolfe MH, Cho HJ, Park IH, Jeong JH, Frisbee E, Dunn C, Davies Z, Milla C, Moss RB,
Thomas EA, Wine JJ. A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and
R117H-5T cystic fibrosis subjects taking ivacaftor. PLoS One 2014; 9: e88564 [PMID: 24520399 DOI:
10.1371/journal.pone.0088564]
WJCC https://www.wjgnet.com November 26, 2019 Volume 7 Issue 22
Caldrer S et al. CFTR functional assays in pancreatitis
3764
Published By Baishideng Publishing Group Inc
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-2238242
E-mail: bpgoffice@wjgnet.com
Help Desk:https://www.f6publishing.com/helpdesk
https://www.wjgnet.com
© 2019 Baishideng Publishing Group Inc. All rights reserved.
